Scarica l'app Stockscreener
4.54
11.33%
-0.58
Pre-mercato:
4.73
0.19
+4.19%
Polaryx Therapeutics Inc Borsa (PLYX) Ultime notizie
Polaryx Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Technical Analysis of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) - TradingView
PLYX Polaryx Therapeutics highlights rare disease pipeline progress in its newly released quarterly earnings report.Verified Stock Signals - Newser
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference - The Manila Times
Polaryx heads to Tay-Sachs family meeting with Phase 2 program - Stock Titan
FDA grants fast track status to Polaryx’s PLX-200 for three rare diseases - Investing.com Nigeria
Polaryx receives U.S. FDA Fast Track Designation for PLX-200 - TipRanks
Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate - marketscreener.com
Polaryx Therapeutics receives U.S. FDA fast track designations for all four indications to be evaluated in the Soteria Basket Trial - marketscreener.com
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial - The Manila Times
FDA fast-tracks Polaryx drug for 4 rare childhood disorders - Stock Titan
Does Polaryx Therapeutics (PLYX) Stock Pay Dividends? (Underperforming) 2026-04-20Real Trader Network - Cổng thông tin điện tử Tỉnh Sơn La
PLYX Should I Buy - Intellectia AI
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times
A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan
Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
What makes Polaryx Therapeutics (PLYX) Stock attractive or not | Price at $5.63, Down 2.26%Shared Buy Zones - Newser
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics, Inc. (PLYX) stock price, news, quote and history - Yahoo Finance UK
PLYX: Polaryx Therapeutics, Inc.Options Chain - Zacks Investment Research
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - Bitget
Polaryx to webcast Needham healthcare presentation on Apr. 16 - Stock Titan
PLYX Stock Analysis: Polaryx Therapeutics Inc. biotech gains 7.54% to hit 8.13 level - Cổng thông tin điện tử tỉnh Lào Cai
Polaryx Therapeutics Inc (NASDAQ: PLYX)Share Price - intelligentinvestor.com.au
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS
Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan
PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView
MSN Money - MSN
Polaryx Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - tipranks.com
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
FDA Fast Track for PLX‑200 targeting rare pediatric disorder - Stock Titan
Should I buy Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):